Clinical Trial Update: A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and anti-tumor activity of cetuximab in combination with cisplatin and 5-fluorouracil in recurrent and/or metastatic head and ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: COMPLETED | Results posted: 2012-08-10